Pharmacological Considerations in Morbidly Obese Patients

Authors

  •   S. S. Nethra Department of Anaesthesiology, Bangalore Medical College and Research Institute, Bengaluru – 560002, Karnataka
  •   D. Shobha Department of Anaesthesiology, Bangalore Medical College and Research Institute, Bengaluru – 560002, Karnataka
  •   Satish Kumar Department of Anaesthesiology, Bangalore Medical College and Research Institute, Bengaluru – 560002, Karnataka

DOI:

https://doi.org/10.4103/kaj/2024/v19i1-4/169643

Keywords:

Body Mass Index, Lean Body Weight, Morbidly Obese

Abstract

With the increased prevalence of obesity globally, knowledge of the altered pharmacological behaviour of anaesthetic drugs is essential for optimal anaesthetic management of morbidly obese patients and requires special dosing regimens. Failure to account for the pharmacokinetic changes associated with obesity can lead to incorrect doses. So awareness of this is necessary for safe and effective care of morbidly obese patients. This article intends to highlight the dosing regimens in morbidly obese patients.

Downloads

Download data is not yet available.

Downloads

Published

2024-10-21

How to Cite

Nethra, S. S., Shobha, D., & Kumar, S. (2024). Pharmacological Considerations in Morbidly Obese Patients. Karnataka Anaesthesia Journal, 19(1-4), 5–14. https://doi.org/10.4103/kaj/2024/v19i1-4/169643

Issue

Volume 19, Issue 1-4, January-June 2021-2024

Section

Review Article
Crossref
Scopus
Google Scholar
Europe PMC

References

World Health Organization. International association for the study of obesity, International Obesity Taskforce. The Asia-Pacific perspective: Redefining obesity and its treatment; 2000. p. 15-21.

Pradeepa R, Mohan V. The changing scenario of the diabetes epidemic implications for India. Indian J Med Res. 2002; 116:121-32.

Barras M, Legg A. Drug dosing in obese adults. Aust Prescr. 2017; 40(5):189-93. https://doi.org/10.18773/ austprescr.2017.053

Eleveld DJ, Proost JH, Absalom AR, Struys MM. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011; 50(11):751-3. https://doi.org/10.2165/11594080-000000000-00000

Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005; 44(10):1051-65. https://doi.org/10.2165/00003088-200544100-00004

. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987; 317(17). https://doi.org/10.1056/ NEJM198710223171717

Smit C, De Hoogd S, Brüggemann RJ, Knibbe CA. Obesity and drug pharmacology; A review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxico. 2018; 14(3):275-85. https://doi.org/10.1080/17425255.2018.1440287

Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokinet. 2000; 39(3):215-31. https://doi.org/10.2165/00003088-200039030-00004

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. https://doi.org/10.1159/000180580

Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010; 49(2):71-87. https://doi.org/10.2165/11318100-000000000-00000

Angeles PC, Robertsen I, Seeberg LT, Krogstad V, Skattebu J, Sandbu R, et al. The influence of bariatric surgery on oral drug bioavailability in patients with obesity: Asystematic review. Obes Rev. 2019; 20(9):1299-311. https://doi.org/10.1111/obr.12869

Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012; 51(5):277-304. https://doi.org/10.2165/11599410-000000000-00000

Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010; 105(Suppl.1):I16-231. https://doi.org/10.1093/bja/aeq312

Hebbes CP, Thompson JP. Pharmacokinetics of anaesthetic drugs at extremes of body weight. BJA Educ. 2018; 18(12):364-70. https://doi.org/10.1016/j.bjae.2018.09.001

Cucuianu M, Popescu TA. Pseudocholinesterase in obese and hyperlipemic subjects. Clinica Chimica Acta. 1968; 22(2):151-5. https://doi.org/10.1016/00098981(68)90351-3

Monk TG, Rietbergen H, Woo T, Fennema H. Use of sugammadex in patients with obesity: A pooled analysis. Am J Ther. 2017; 24(5):e507-16. https://doi.org/10.1097/ MJT.0000000000000305

Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: A simple solution to a big problem. Clin Pharmacol Ther. 2007; 82(5):505-8. https://doi.org/10.1038/sj.clpt.6100381

Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol. 2011; 25(1):27-36. https://doi.org/10.1016/j.bpa.2010.12.002

Sameh AA. Opioid-free anesthesia in morbid obese patients: Review article. Anest Inten Care Med. 2020; 11(1):555803. https://doi.org/10.19080/JAICM.2020.11.555803

Cortinez LI, Anderson BJ, Penna A, Olivares L, Munoz HR, Holford NH, et al. Influence of obesity on propofol pharmacokinetics: Derivation of a pharmacokinetic model. Br J Anaesth. 2010; 105(4):448-56. https://doi.org/10.1093/bja/aeq195

Servin FS. TCI in special patients groups: The elderly and obese. Total intravenous anesthesia and target controlled infusions, SpringerLink; 2017. p. 571-8. https://doi.org/10.1007/978-3-319-47609-4_29

Most read articles by the same author(s)